(DXCM) DexCom - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2521311074
Stock: Continuous Glucose Monitor, Sensor, Transmitter, Receiver
Total Rating 45
Risk 90
Buy Signal -0.95
| Risk 5d forecast | |
|---|---|
| Volatility | 43.6% |
| Relative Tail Risk | -19.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.21 |
| Alpha | -30.16 |
| Character TTM | |
|---|---|
| Beta | 0.728 |
| Beta Downside | 0.274 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.95% |
| CAGR/Max DD | -0.23 |
EPS (Earnings per Share)
Revenue
Description: DXCM DexCom March 03, 2026
DexCom, Inc. (NASDAQ: DXCM) designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health, selling products such as the G7, G6, ONE+, and Stelo directly to endocrinologists, physicians, and diabetes educators. Founded in 1999 and headquartered in San Diego, the company operates globally across the health-care equipment sub-industry.
In the most recent quarter (Q2 2024), DexCom reported revenue of $1.13 billion, a 12% year-over-year increase driven by strong adoption of the G7 system and expanding reimbursement coverage in Europe and the United States. The CGM market is projected to grow at a CAGR of ~10% through 2028, with DexCom holding roughly 35% market share, second only to its main competitor. Additionally, the company’s operating margin improved to 22% as cost efficiencies from the newer G7 platform offset rising R&D spend.
For a deeper dive into the valuation metrics and competitive landscape, consider reviewing the analysis on ValueRay.
Headlines to watch out for
- CGM system adoption drives revenue growth
- Regulatory approvals expand market access for new devices
- Reimbursement policies impact product affordability and sales
- Competition from alternative glucose monitoring solutions affects market share
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 836.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 7.26 > 1.0 |
| NWC/Revenue: 40.56% < 20% (prev 33.95%; Δ 6.60% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.44b > Net Income 836.3m |
| Net Debt (472.0m) to EBITDA (1.34b): 0.35 < 3 |
| Current Ratio: 1.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (398.9m) vs 12m ago -1.92% < -2% |
| Gross Margin: 60.10% > 18% (prev 0.60%; Δ 5950 % > 0.5%) |
| Asset Turnover: 72.71% > 50% (prev 62.19%; Δ 10.51% > 0%) |
| Interest Coverage Ratio: 59.28 > 6 (EBITDA TTM 1.34b / Interest Expense TTM 18.3m) |
Altman Z'' 5.09
| A: 0.30 (Total Current Assets 4.03b - Total Current Liabilities 2.14b) / Total Assets 6.34b |
| B: 0.38 (Retained Earnings 2.43b / Total Assets 6.34b) |
| C: 0.17 (EBIT TTM 1.08b / Avg Total Assets 6.41b) |
| D: 0.71 (Book Value of Equity 2.55b / Total Liabilities 3.59b) |
| Altman-Z'' Score: 5.09 = AAA |
Beneish M -3.01
| DSRI: 1.08 (Receivables 1.29b/1.03b, Revenue 4.66b/4.03b) |
| GMI: 1.01 (GM 60.10% / 60.46%) |
| AQI: 0.88 (AQ_t 0.11 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 4.66b / 4.03b) |
| TATA: -0.10 (NI 836.3m - CFO 1.44b) / TA 6.34b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of DXCM shares?
As of March 10, 2026, the stock is trading at USD 68.10 with a total of 3,930,510 shares traded.
Over the past week, the price has changed by -7.70%, over one month by -2.94%, over three months by +3.78% and over the past year by -3.70%.
Over the past week, the price has changed by -7.70%, over one month by -2.94%, over three months by +3.78% and over the past year by -3.70%.
Is DXCM a buy, sell or hold?
DexCom has received a consensus analysts rating of 4.54.
Therefore, it is recommended to buy DXCM.
- StrongBuy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DXCM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.9 | 26.1% |
| Analysts Target Price | 85.9 | 26.1% |
DXCM Fundamental Data Overview March 05, 2026
P/E Trailing = 35.3043
P/E Forward = 29.7619
P/S = 6.1138
P/B = 10.3406
P/EG = 1.0897
Revenue TTM = 4.66b USD
EBIT TTM = 1.08b USD
EBITDA TTM = 1.34b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 472.0m USD (from netDebt column, last quarter)
Enterprise Value = 27.89b USD (28.50b + Debt 1.39b - CCE 2.00b)
Interest Coverage Ratio = 59.28 (Ebit TTM 1.08b / Interest Expense TTM 18.3m)
EV/FCF = 25.89x (Enterprise Value 27.89b / FCF TTM 1.08b)
FCF Yield = 3.86% (FCF TTM 1.08b / Enterprise Value 27.89b)
FCF Margin = 23.11% (FCF TTM 1.08b / Revenue TTM 4.66b)
Net Margin = 17.94% (Net Income TTM 836.3m / Revenue TTM 4.66b)
Gross Margin = 60.10% ((Revenue TTM 4.66b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 62.93% (prev 60.48%)
Tobins Q-Ratio = 4.40 (Enterprise Value 27.89b / Total Assets 6.34b)
Interest Expense / Debt = 0.30% (Interest Expense 4.20m / Debt 1.39b)
Taxrate = 21.54% (73.4m / 340.7m)
NOPAT = 851.1m (EBIT 1.08b * (1 - 21.54%))
Current Ratio = 1.88 (Total Current Assets 4.03b / Total Current Liabilities 2.14b)
Debt / Equity = 0.51 (Debt 1.39b / totalStockholderEquity, last quarter 2.75b)
Debt / EBITDA = 0.35 (Net Debt 472.0m / EBITDA 1.34b)
Debt / FCF = 0.44 (Net Debt 472.0m / FCF TTM 1.08b)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.04% (Net Income 836.3m / Total Assets 6.34b)
RoE = 32.44% (Net Income TTM 836.3m / Total Stockholder Equity 2.58b)
RoCE = 28.41% (EBIT 1.08b / Capital Employed (Equity 2.58b + L.T.Debt 1.24b))
RoIC = 18.02% (NOPAT 851.1m / Invested Capital 4.72b)
WACC = 8.21% (E(28.50b)/V(29.89b) * Re(8.60%) + D(1.39b)/V(29.89b) * Rd(0.30%) * (1-Tc(0.22)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.07%
[DCF] Terminal Value 80.57% ; FCFF base≈898.6m ; Y1≈1.11b ; Y5≈1.89b
[DCF] Fair Price = 78.26 (EV 30.59b - Net Debt 472.0m = Equity 30.12b / Shares 384.9m; r=8.21% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 77.13 | EPS CAGR: 76.95% | SUE: 0.56 | # QB: 0
Revenue Correlation: 95.09 | Revenue CAGR: 20.35% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.60 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+7 | Analysts=22
EPS current Year (2026-12-31): EPS=2.50 | Chg7d=+0.000 | Chg30d=+0.025 | Revisions Net=+5 | Growth EPS=+19.5% | Growth Revenue=+12.3%
EPS next Year (2027-12-31): EPS=2.99 | Chg7d=+0.001 | Chg30d=+0.002 | Revisions Net=+3 | Growth EPS=+19.7% | Growth Revenue=+12.4%
[Analyst] Revisions Ratio: +0.41 (12 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 8.6% - Earnings Yield 2.8%)
[Growth] Growth Spread = +6.3% (Analyst 12.1% - Implied 5.8%)
P/E Forward = 29.7619
P/S = 6.1138
P/B = 10.3406
P/EG = 1.0897
Revenue TTM = 4.66b USD
EBIT TTM = 1.08b USD
EBITDA TTM = 1.34b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 472.0m USD (from netDebt column, last quarter)
Enterprise Value = 27.89b USD (28.50b + Debt 1.39b - CCE 2.00b)
Interest Coverage Ratio = 59.28 (Ebit TTM 1.08b / Interest Expense TTM 18.3m)
EV/FCF = 25.89x (Enterprise Value 27.89b / FCF TTM 1.08b)
FCF Yield = 3.86% (FCF TTM 1.08b / Enterprise Value 27.89b)
FCF Margin = 23.11% (FCF TTM 1.08b / Revenue TTM 4.66b)
Net Margin = 17.94% (Net Income TTM 836.3m / Revenue TTM 4.66b)
Gross Margin = 60.10% ((Revenue TTM 4.66b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 62.93% (prev 60.48%)
Tobins Q-Ratio = 4.40 (Enterprise Value 27.89b / Total Assets 6.34b)
Interest Expense / Debt = 0.30% (Interest Expense 4.20m / Debt 1.39b)
Taxrate = 21.54% (73.4m / 340.7m)
NOPAT = 851.1m (EBIT 1.08b * (1 - 21.54%))
Current Ratio = 1.88 (Total Current Assets 4.03b / Total Current Liabilities 2.14b)
Debt / Equity = 0.51 (Debt 1.39b / totalStockholderEquity, last quarter 2.75b)
Debt / EBITDA = 0.35 (Net Debt 472.0m / EBITDA 1.34b)
Debt / FCF = 0.44 (Net Debt 472.0m / FCF TTM 1.08b)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.04% (Net Income 836.3m / Total Assets 6.34b)
RoE = 32.44% (Net Income TTM 836.3m / Total Stockholder Equity 2.58b)
RoCE = 28.41% (EBIT 1.08b / Capital Employed (Equity 2.58b + L.T.Debt 1.24b))
RoIC = 18.02% (NOPAT 851.1m / Invested Capital 4.72b)
WACC = 8.21% (E(28.50b)/V(29.89b) * Re(8.60%) + D(1.39b)/V(29.89b) * Rd(0.30%) * (1-Tc(0.22)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.07%
[DCF] Terminal Value 80.57% ; FCFF base≈898.6m ; Y1≈1.11b ; Y5≈1.89b
[DCF] Fair Price = 78.26 (EV 30.59b - Net Debt 472.0m = Equity 30.12b / Shares 384.9m; r=8.21% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 77.13 | EPS CAGR: 76.95% | SUE: 0.56 | # QB: 0
Revenue Correlation: 95.09 | Revenue CAGR: 20.35% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.60 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+7 | Analysts=22
EPS current Year (2026-12-31): EPS=2.50 | Chg7d=+0.000 | Chg30d=+0.025 | Revisions Net=+5 | Growth EPS=+19.5% | Growth Revenue=+12.3%
EPS next Year (2027-12-31): EPS=2.99 | Chg7d=+0.001 | Chg30d=+0.002 | Revisions Net=+3 | Growth EPS=+19.7% | Growth Revenue=+12.4%
[Analyst] Revisions Ratio: +0.41 (12 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 8.6% - Earnings Yield 2.8%)
[Growth] Growth Spread = +6.3% (Analyst 12.1% - Implied 5.8%)